Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Centre Asset Management LLC

Centre Asset Management LLC lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 6.7% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 70,692 shares of the specialty pharmaceutical company's stock after selling 5,111 shares during the period. Jazz Pharmaceuticals accounts for approximately 2.3% of Centre Asset Management LLC's holdings, making the stock its 15th biggest position. Centre Asset Management LLC owned about 0.12% of Jazz Pharmaceuticals worth $8,776,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Fuller & Thaler Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $59,668,000. Dimensional Fund Advisors LP lifted its stake in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp raised its stake in shares of Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock valued at $62,659,000 after acquiring an additional 296,800 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. This represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Seamus Mulligan purchased 1,621 shares of the stock in a transaction on Monday, May 12th. The stock was acquired at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the acquisition, the director now owns 101,621 shares of the company's stock, valued at $10,466,963. The trade was a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders sold 13,123 shares of company stock worth $1,772,966 over the last three months. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $1.04 during trading hours on Monday, reaching $109.11. 270,589 shares of the company traded hands, compared to its average volume of 1,076,532. The stock has a market capitalization of $6.73 billion, a P/E ratio of 15.37, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The business has a fifty day moving average price of $109.72 and a 200-day moving average price of $121.35.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Jazz Pharmaceuticals's quarterly revenue was down .5% compared to the same quarter last year. During the same period last year, the firm earned $2.68 earnings per share. Equities analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several research analyst reports. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Piper Sandler reissued an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Royal Bank of Canada cut their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $182.79.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.